Health
Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®
Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at riskNovo Nordisk takes decisive legal action to stop Hims’ illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetesNovo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded dr
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sq36MpNFOiz.w6RiXrpsqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting their health at risk","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Novo Nordisk takes decisive legal action to stop Hims’ illegal conduct, protect public health, and defend the scientific innovations that deliver better health outcomes to Americans living with serious chronic diseases like obesity and diabetes","length":244,"tagName":"p"}]},{"val":[{"type":"text","content":"Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages","length":159,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":568,"olType":false},{"type":"text","content":"Plainsboro, NJ, US and Bagsværd, Denmark, February 9, 2026 – Novo Nordisk announced today that it has filed a lawsuit against telehealth company Hims & Hers (“Hims”), for infringing US Patent 8,129,343 with Hims’ compounded semaglutide products for the US market. Hims has engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs. This includes Hims’ recent launch, and two days later, abrupt discontinuance of its “Compounded GLP-1 Pill,” which came on the heels of Novo Nordisk’s introduction of the Wegovy® pill, the first and only FDA-approved GLP-1 pill for weight loss. Hims continues to unlawfully mass compound injectable versions, made with inauthentic API, and these knock-offs are putting patient health and wellbeing at risk. ","length":886,"tagName":"p"},{"type":"text","content":"“Throughout Novo Nordisk’s 103-year-long history,...